India markets close in 2 hours 59 minutes

Medtronic plc (MDT)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
131.31+0.63 (+0.48%)
At close: 4:00PM EDT
Sign in to post a message.
  • B
    Bill mddb
    The Simply Wall St article about MDT's ROE is misleading. You have to "normalize" any calculated metric during a trailing 12 month period which includes heavy, one-time revenue deferrals due to covid. The article is a hit piece to get clicks. Buy some today.
  • P
    P
    If you’re tired of watching paint dry, hop over to Abbott. It’s eating MDT’s lunch.
  • J
    Joe Smoe
    $SENS conversation
    $SENS will gain market share from $DXCM, $MDT, $PODD, just a matter of time, go $SENS
  • J
    Jerry
    $SENS conversation
    $SENS New data released, strong accuracy for 180 day CGM sensor!
    https://www.senseonics.com/investor-relations/news-releases/2021/06-03-2021-210515226

    $DXCM $MDT $ABT
  • K
    Km
    let's go
  • J
    Jasper
    Safest long term investment
  • D
    Darbyred
    Good interview of MDT'S CEO on CNBC. Future for MDT and its shareholders is looking great.
  • B
    Bill mddb
    The revenue outlook for 9% growth FY 2022 ending 4/30/22 is good news. There is no doubt some catch-up of deferred spending, but still impressive. That's what you see from Stryker, a much smaller base to grow. There should be some LT accumulation coming to keep a bid in for MDT.
  • S
    Scott
    It's like the market doesn't even care at least 14 people have died using Medtronic's HVAD Implantable Heart Pump...
  • T
    Terry
    MDT beats on top/bottom lines, increases dividend!
  • B
    Bill mddb
    Looks like the outgoing momentum traders are being replaced. Yesterday no doubt saw traders taking profits, but the MDT provided 9% revenue growth this year is very impressive. There should be some accumulation from income & value funds to drive the share price. MDT is a Buffett stock, a dividend aristocrat with some growth. Even if FY 2023, starting 5/1/22 is 5% revenue growth it will be a blockbuster year. They have become good at managing expectations -- the current $5.75 est. for FY 22 should come in over $6. I'm sure they would like to raise the outlook as the year progresses -- just like they were doing before the plague hit.
  • J
    JL Prestige
    Great results! Lots of cash on hand and #MDT milestone 3 of 4 expected completion this month.... GLTA longs
  • l
    letmebehonest
    Medtronik must buy Buy mmat glucowise and capture dexcom market
  • R
    REDD
    This stock is not worth the price. MDT should be SHORTED. Food for thought Total Expenses 24.3mil
    Total income 3.1mil. Come on.
  • s
    stocktargetadvisor
    $MDT
    Maintains Oppenheimer Holdings Outperform USD 134 » USD 147
    Maintains Raymond James Financial Outperform USD 128 » USD 135
    Reiterated by Citigroup Buy USD 133 » USD 143
    Maintains SVB Leerink Market Perform USD 129 » USD 138
    Maintains Deutsche Bank Buy USD 134 » USD 149
  • R
    Rob
    Cover shorty
  • I
    Irwin
    NMRD also has a glucose monitoring product for type 2 diabetes that works as well or better then MDTs products. Any comments or anyone here own both stocks ?
  • R
    Randy
    MDT beats on top/bottom lines, increases dividend and down we go. Insane Trading
  • I
    Irwin
    MDT dibeaties glucose monitoring product is not as good as NMRD products. Anybody here own both MDT & NMRD stock ? ..
  • R
    Rajesh
    short MDT. Earning will be bad tomorrow!!